{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T09:32:56Z","timestamp":1778232776851,"version":"3.51.4"},"reference-count":34,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"abstract":"<jats:sec>\n                  <jats:title\/>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>BACKGROUND AND OBJECTIVES:<\/jats:title>\n                  <jats:p>Adolescents represent the largest age group that presents to emergency departments (ED) for synthetic cannabinoid (SC) toxicity; however, the neurotoxic effects of acute SC exposures in this group are understudied. Our aim was to characterize the neuropsychiatric presentation of adolescents with SC-related exposure in the ED compared with those with traditional cannabis exposure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS:<\/jats:title>\n                  <jats:p>A multicenter registry of clinical information prospectively collected by medical toxicologists (Toxicology Investigators Consortium Case Registry) was reviewed for adolescents presenting to the ED after SC or cannabis exposure from 2010 through 2018. Associations were measured between drug exposures and neuropsychiatric symptoms and\/or signs. Exposures were classified into 4 groups: SC-only exposure, SC-polydrug exposures, cannabis-only exposure, and cannabis-polydrug exposures.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS:<\/jats:title>\n                  <jats:p>Adolescents presenting to the ED with SC-only exposure (n = 107) had higher odds of coma and\/or central nervous system depression (odds ratio [OR] 3.42; 95% confidence interval [CI] 1.51\u20137.75) and seizures (OR 3.89; 95% CI 1.39\u201310.94) than those with cannabis-only exposure (n = 86). SC-only drug exposure was associated with lower odds of agitation than cannabis-only exposure (OR 0.18; 95% CI 0.10\u20130.34). In contrast, the group with SC-polydrug exposures (n = 38) had higher odds of agitation (OR 3.11; 95% CI 1.56\u20137.44) and seizures (OR 4.8; 95% CI 1.80\u201312.74) than the cannabis-polydrug exposures group (n = 117).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS:<\/jats:title>\n                  <jats:p>In this multisite cohort of US adolescents assessed in the ED, SC exposure was associated with higher odds of neuropsychiatric morbidity than cannabis exposure providing a distinct neurospychiatric profile of acute SC toxicity in adolescents.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1542\/peds.2018-2690","type":"journal-article","created":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T12:25:12Z","timestamp":1562588712000},"source":"Crossref","is-referenced-by-count":21,"title":["Neuropsychiatric Sequelae in Adolescents With Acute Synthetic Cannabinoid Toxicity"],"prefix":"10.1542","volume":"144","author":[{"given":"Sarah Ann R.","family":"Anderson","sequence":"first","affiliation":[{"name":"Departments of Pediatrics and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna M.","family":"Oprescu","sequence":"additional","affiliation":[{"name":"Departments of Psychiatry, Neuroscience, and Pharmacological Science, Icahn School of Medicine at Mount Sinai, New York, New York;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"P. Calello","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, New Jersey Medical School, Rutgers University, Newark, New Jersey; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Monte","sequence":"additional","affiliation":[{"name":"Departments of Emergency Medicine and Pharmaceutical Sciences, School of Medicine, University of Colorado, Aurora, Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter S.","family":"Dayan","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics and"},{"name":"Emergency Medicine, Columbia University Herbert and Florence Irving Medical Center, New York, New York;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmin L.","family":"Hurd","sequence":"additional","affiliation":[{"name":"Departments of Psychiatry, Neuroscience, and Pharmacological Science, Icahn School of Medicine at Mount Sinai, New York, New York;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex F.","family":"Manini","sequence":"additional","affiliation":[{"name":"Division of Medical Toxicology, Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai and Elmhurst Hospital Center, New York, New York;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the ToxIC Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2019,8,1]]},"reference":[{"issue":"22","key":"2021121012451021600_B1","first-page":"618","article-title":"Notes from the field: increase in reported adverse health effects related to synthetic cannabinoid use - United States, January-May 2015.","volume":"64","author":"Law","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"2021121012451021600_B2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1056\/NEJMp1505328","article-title":"Synthetic cannabinoid-related illnesses and deaths.","volume":"373","author":"Trecki","year":"2015","journal-title":"N Engl J Med"},{"key":"2021121012451021600_B3","author":"United Nations Office on Drugs and Crime."},{"key":"2021121012451021600_B4","author":"United Nations Office on Drugs and Crime","year":"2013"},{"issue":"3","key":"2021121012451021600_B5","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1476-5381.2009.00582.x","article-title":"JWH018, a common constituent of \u2018Spice\u2019 herbal blends, is a potent and efficacious cannabinoid CB receptor agonist.","volume":"160","author":"Atwood","year":"2010","journal-title":"Br J Pharmacol"},{"issue":"4","key":"2021121012451021600_B6","doi-asserted-by":"crossref","first-page":"e20171330","DOI":"10.1542\/peds.2017-1330","article-title":"Synthetic cannabinoid use among high school seniors.","volume":"140","author":"Palamar","year":"2017","journal-title":"Pediatrics"},{"issue":"5","key":"2021121012451021600_B7","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11920-016-0694-1","article-title":"Adverse effects of synthetic cannabinoids: management of acute toxicity and withdrawal.","volume":"18","author":"Cooper","year":"2016","journal-title":"Curr Psychiatry Rep"},{"issue":"4","key":"2021121012451021600_B8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s13181-016-0558-4","article-title":"Clinical effects of synthetic cannabinoid receptor agonists compared with marijuana in emergency department patients with acute drug overdose.","volume":"12","author":"Zaurova","year":"2016","journal-title":"J Med Toxicol"},{"key":"2021121012451021600_B9","doi-asserted-by":"publisher","DOI":"10.1097\/PEC.0000000000001454","article-title":"Synthetic cannabinoid exposure in adolescents presenting for emergency care [published online ahead of print March 12, 2018].","author":"Gilley","journal-title":"Pediatr Emerg Care"},{"issue":"4","key":"2021121012451021600_B10","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.annemergmed.2012.03.007","article-title":"A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010.","volume":"60","author":"Hoyte","year":"2012","journal-title":"Ann Emerg Med"},{"key":"2021121012451021600_B11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.drugalcdep.2016.07.018","article-title":"Age, period, and cohort effects in synthetic cannabinoid use among US adolescents, 2011-2015.","volume":"166","author":"Keyes","year":"2016","journal-title":"Drug Alcohol Depend"},{"issue":"27","key":"2021121012451021600_B12","doi-asserted-by":"crossref","first-page":"692","DOI":"10.15585\/mmwr.mm6527a2","article-title":"Acute poisonings from synthetic cannabinoids - 50 U.S. Toxicology Investigators Consortium Registry sites, 2010-2015.","volume":"65","author":"Riederer","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"2021121012451021600_B13","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1177\/0269881115574493","article-title":"Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample.","volume":"29","author":"Winstock","year":"2015","journal-title":"J Psychopharmacol"},{"key":"2021121012451021600_B14","volume-title":"Update: Drug-Related Emergency Department Visits Involving Synthetic Cannabinoids","author":"National Institute on Drug Abuse","year":"2014"},{"issue":"5","key":"2021121012451021600_B15","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jemermed.2015.06.053","article-title":"Synthetic cannabinoid abuse in adolescents: a case series.","volume":"49","author":"Besli","year":"2015","journal-title":"J Emerg Med"},{"issue":"4","key":"2021121012451021600_B16","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s13181-011-0185-z","article-title":"The Toxicology Investigators Consortium Case Registry-the 2010 experience.","volume":"7","author":"Brent","year":"2011","journal-title":"J Med Toxicol"},{"issue":"3","key":"2021121012451021600_B17","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s13181-016-0580-6","article-title":"The Toxicology Investigators Consortium Case Registry-the 2015 experience.","volume":"12","author":"Farrugia","year":"2016","journal-title":"J Med Toxicol"},{"issue":"4","key":"2021121012451021600_B18","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s13181-015-0507-7","article-title":"The Toxicology Investigators Consortium Case Registry\u2013the 2014 experience.","volume":"11","author":"Rhyee","year":"2015","journal-title":"J Med Toxicol"},{"issue":"4","key":"2021121012451021600_B19","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s13181-014-0417-0","article-title":"The Toxicology Investigators Consortium Case Registry-the 2013 experience.","volume":"10","author":"Rhyee","year":"2014","journal-title":"J Med Toxicol"},{"issue":"4","key":"2021121012451021600_B20","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s13181-013-0352-5","article-title":"The Toxicology Investigators Consortium Case Registry\u2013the 2012 experience.","volume":"9","author":"Wiegand","year":"2013","journal-title":"J Med Toxicol"},{"issue":"4","key":"2021121012451021600_B21","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s13181-012-0264-9","article-title":"The Toxicology Investigators Consortium Case Registry\u2013the 2011 experience.","volume":"8","author":"Wiegand","year":"2012","journal-title":"J Med Toxicol"},{"issue":"3","key":"2021121012451021600_B22","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s13181-018-0679-z","article-title":"The Toxicology Investigators Consortium Case Registry-the 2017 annual report.","volume":"14","author":"Farrugia","year":"2018","journal-title":"J Med Toxicol"},{"key":"2021121012451021600_B23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.taap.2017.10.007","article-title":"Synthetic cannabinoid AM2201 induces seizures: involvement of cannabinoid CB1 receptors and glutamatergic transmission.","volume":"338","author":"Funada","year":"2018","journal-title":"Toxicol Appl Pharmacol"},{"key":"2021121012451021600_B24","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.bbr.2014.05.029","article-title":"Cannabinoids negatively modulate striatal glutamate and dopamine release and behavioural output of acute D-amphetamine.","volume":"270","author":"Polissidis","year":"2014","journal-title":"Behav Brain Res"},{"issue":"4","key":"2021121012451021600_B25","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s13181-016-0571-7","article-title":"Acute toxicity associated with use of 5F-derivations of synthetic cannabinoid receptor agonists with analytical confirmation.","volume":"12","author":"Abouchedid","year":"2016","journal-title":"J Med Toxicol"},{"issue":"2","key":"2021121012451021600_B26","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jemermed.2012.07.061","article-title":"Synthetic cannabinoid intoxication: a case series and review.","volume":"44","author":"Harris","year":"2013","journal-title":"J Emerg Med"},{"issue":"6","key":"2021121012451021600_B27","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1080\/15563650.2017.1393082","article-title":"Acute side effects after consumption of the new synthetic cannabinoids AB-CHMINACA and MDMB-CHMICA.","volume":"56","author":"Hermanns-Clausen","year":"2018","journal-title":"Clin Toxicol (Phila)"},{"issue":"1","key":"2021121012451021600_B28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/15563650.2015.1110590","article-title":"A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment.","volume":"54","author":"Tait","year":"2016","journal-title":"Clin Toxicol (Phila)"},{"key":"2021121012451021600_B29","volume-title":"Monitoring the Future National Survey Results on Drug Use, 1975-2016: Overview, Key Findings on Adolescent Drug Use","author":"Johnston","year":"2017"},{"issue":"4","key":"2021121012451021600_B30","doi-asserted-by":"crossref","first-page":"e20162675","DOI":"10.1542\/peds.2016-2675","article-title":"Health risk behaviors with synthetic cannabinoids versus marijuana.","volume":"139","author":"Clayton","year":"2017","journal-title":"Pediatrics"},{"issue":"2","key":"2021121012451021600_B31","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1080\/08897077.2013.846288","article-title":"A survey of synthetic cannabinoid consumption by current cannabis users.","volume":"35","author":"Gunderson","year":"2014","journal-title":"Subst Abus"},{"issue":"6","key":"2021121012451021600_B32","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1177\/0269881116684336","article-title":"Acute and residual effects in adolescent rats resulting from exposure to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA.","volume":"31","author":"Kevin","year":"2017","journal-title":"J Psychopharmacol"},{"issue":"10","key":"2021121012451021600_B33","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/j.ajem.2017.04.044","article-title":"Clinical and financial implications of emergency department visits for synthetic marijuana.","volume":"35","author":"Rowley","year":"2017","journal-title":"Am J Emerg Med"},{"issue":"8","key":"2021121012451021600_B34","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1046\/j.1360-0443.2001.968118711.x","article-title":"The reliability of self-reported age of onset of tobacco, alcohol and illicit drug use.","volume":"96","author":"Johnson","year":"2001","journal-title":"Addiction"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2018-2690\/1077261\/peds_20182690.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2018-2690\/1077261\/peds_20182690.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T01:20:46Z","timestamp":1639185646000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/144\/2\/e20182690\/76880\/Neuropsychiatric-Sequelae-in-Adolescents-With"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,1]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,8,1]]},"published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2018-2690","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,1]]},"article-number":"e20182690"}}